In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response.

Advanced Materials
Worapol NgamcherdtrakulWassana Yantasee

Abstract

The success of immunotherapy with immune checkpoint inhibitors (ICIs) in a subset of individuals has been very exciting. However, in many cancers, responses to current ICIs are modest and are seen only in a small subsets of patients. Herein, a widely applicable approach that increases the benefit of ICIs is reported. Intratumoral administration of augmenting immune response and inhibiting suppressive environment of tumors-AIRISE-02 nanotherapeutic that co-delivers CpG and STAT3 siRNA-results in not only regression of the injected tumor, but also tumors at distant sites in multiple tumor model systems. In particular, three doses of AIRISE-02 in combination with systemic ICIs completely cure both treated and untreated aggressive melanoma tumors in 63% of mice, while ICIs alone do not cure any mice. A long-term memory immune effect is also reported. AIRISE-02 is effective in breast and colon tumor models as well. Lastly, AIRISE-02 is well tolerated in mice and nonhuman primates. This approach combines multiple therapeutic agents into a single nanoconstruct to create whole-body immune responses across multiple cancer types. Being a local therapeutic, AIRISE-02 circumvents regulatory challenges of systemic nanoparticle delivery, fac...Continue Reading

References

Jan 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·G HartmannA M Krieg
Jun 29, 2005·The Journal of Experimental Medicine·Alan D RobertsDavid L Woodland
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer C C HuR Charles Coombes
Jul 12, 2007·Proceedings of the National Academy of Sciences of the United States of America·Akihiro KimuraTadamitsu Kishimoto
May 16, 2008·Current Opinion in Immunology·Marcin Kortylewski, Hua Yu
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Barbara G MolenkampTanja D de Gruijl
Oct 18, 2008·Expert Review of Anticancer Therapy·Robin J PrestwichFiona Errington
Jun 16, 2009·Nature Materials·Andre E NelMike Thompson
Sep 1, 2007·Update on Cancer Therapeutics·Antoni Ribas
Jun 3, 2010·Current Topics in Microbiology and Immunology·Heehyoung LeeHua Yu
Apr 22, 2011·Expert Review of Vaccines·Christian BodeDennis M Klinman
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vera HirshJoan H Schiller
Jun 3, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tomoko Iwata-KajiharaYutaka Kawakami
Jan 11, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yuko ShirotaDennis M Klinman
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Feb 8, 2013·Accounts of Chemical Research·Derrick TarnC Jeffrey Brinker
Sep 6, 2014·Chinese Journal of Cancer·Elad SharonHelen X Chen
Oct 31, 2014·Science Translational Medicine·Evan PhillipsMichelle S Bradbury
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Jun 23, 2015·Advanced Functional Materials·Worapol NgamcherdtrakulWassana Yantasee
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Nov 14, 2015·Journal of the National Cancer Institute·Jeffrey E Gershenwald, Gery P Guy
Sep 24, 2016·Journal for Immunotherapy of Cancer·Hasan RehmanHoward L Kaufman
Jul 15, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Achim K MoestaPedro J Beltran
Oct 4, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bas D KosterTanja D de Gruijl
Dec 15, 2017·Advanced Materials·Ashley V KrollLiangfang Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.